205 related articles for article (PubMed ID: 38163846)
21. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites.
Grigoriadis DE; Smith E; Hoare SRJ; Madan A; Bozigian H
J Pharmacol Exp Ther; 2017 Jun; 361(3):454-461. PubMed ID: 28404690
[TBL] [Abstract][Full Text] [Related]
22. Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum.
Pifl C; Rajput A; Reither H; Blesa J; Cavada C; Obeso JA; Rajput AH; Hornykiewicz O
J Neurosci; 2014 Jun; 34(24):8210-8. PubMed ID: 24920625
[TBL] [Abstract][Full Text] [Related]
23. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter.
Cozzi NV; Gopalakrishnan A; Anderson LL; Feih JT; Shulgin AT; Daley PF; Ruoho AE
J Neural Transm (Vienna); 2009 Dec; 116(12):1591-9. PubMed ID: 19756361
[TBL] [Abstract][Full Text] [Related]
24. Storage of neural histamine and histaminergic neurotransmission is VMAT2 dependent in the zebrafish.
Puttonen HAJ; Semenova S; Sundvik M; Panula P
Sci Rep; 2017 Jun; 7(1):3060. PubMed ID: 28596586
[TBL] [Abstract][Full Text] [Related]
25. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine.
Teng L; Crooks PA; Dwoskin LP
J Neurochem; 1998 Jul; 71(1):258-65. PubMed ID: 9648873
[TBL] [Abstract][Full Text] [Related]
26. Specific derivatization of the vesicle monoamine transporter with novel carrier-free radioiodinated reserpine and tetrabenazine photoaffinity labels.
Sievert MK; Hajipour AR; Ruoho AE
Anal Biochem; 2007 Aug; 367(1):68-78. PubMed ID: 17559790
[TBL] [Abstract][Full Text] [Related]
27. Vesicular monoamine and glutamate transporters select distinct synaptic vesicle recycling pathways.
Onoa B; Li H; Gagnon-Bartsch JA; Elias LA; Edwards RH
J Neurosci; 2010 Jun; 30(23):7917-27. PubMed ID: 20534840
[TBL] [Abstract][Full Text] [Related]
28. Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter.
Zucker M; Weizman A; Rehavi M
Life Sci; 2001 Sep; 69(19):2311-7. PubMed ID: 11669473
[TBL] [Abstract][Full Text] [Related]
29. Reserpine- and tetrabenazine-sensitive transport of (3)H-histamine by the neuronal isoform of the vesicular monoamine transporter.
Erickson JD; Eiden LE; Schafer MK; Weihe E
J Mol Neurosci; 1995; 6(4):277-87. PubMed ID: 8860238
[TBL] [Abstract][Full Text] [Related]
30. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
Niemann N; Jankovic J
Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
[TBL] [Abstract][Full Text] [Related]
31. Normal biogenesis and cycling of empty synaptic vesicles in dopamine neurons of vesicular monoamine transporter 2 knockout mice.
Croft BG; Fortin GD; Corera AT; Edwards RH; Beaudet A; Trudeau LE; Fon EA
Mol Biol Cell; 2005 Jan; 16(1):306-15. PubMed ID: 15496457
[TBL] [Abstract][Full Text] [Related]
32. Assessing Vesicular Monoamine Transport and Toxicity Using Fluorescent False Neurotransmitters.
Black CA; Bucher ML; Bradner JM; Jonas L; Igarza K; Miller GW
Chem Res Toxicol; 2021 May; 34(5):1256-1264. PubMed ID: 33378168
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
Provencher BA; Eshleman AJ; Johnson RA; Shi X; Kryatova O; Nelson J; Tian J; Gonzalez M; Meltzer PC; Janowsky A
J Med Chem; 2018 Oct; 61(20):9121-9131. PubMed ID: 30240563
[TBL] [Abstract][Full Text] [Related]
34. VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine).
Harriott ND; Williams JP; Smith EB; Bozigian HP; Grigoriadis DE
Prog Med Chem; 2018; 57(1):87-111. PubMed ID: 29680151
[TBL] [Abstract][Full Text] [Related]
35. Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport.
Thiriot DS; Ruoho AE
J Biol Chem; 2001 Jul; 276(29):27304-15. PubMed ID: 11375404
[TBL] [Abstract][Full Text] [Related]
36. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.
Zai CC; Tiwari AK; Mazzoco M; de Luca V; Müller DJ; Shaikh SA; Lohoff FW; Freeman N; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL
J Psychiatr Res; 2013 Nov; 47(11):1760-5. PubMed ID: 24018103
[TBL] [Abstract][Full Text] [Related]
37. VMAT2 Inhibitors in Neuropsychiatric Disorders.
Tarakad A; Jimenez-Shahed J
CNS Drugs; 2018 Dec; 32(12):1131-1144. PubMed ID: 30306450
[TBL] [Abstract][Full Text] [Related]
38. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
Stahl SM
CNS Spectr; 2018 Aug; 23(4):239-247. PubMed ID: 30160230
[TBL] [Abstract][Full Text] [Related]
39. Transport of histamine by vesicular monoamine transporter-2.
Merickel A; Edwards RH
Neuropharmacology; 1995 Nov; 34(11):1543-7. PubMed ID: 8606801
[TBL] [Abstract][Full Text] [Related]
40. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.
Erickson JD; Schafer MK; Bonner TI; Eiden LE; Weihe E
Proc Natl Acad Sci U S A; 1996 May; 93(10):5166-71. PubMed ID: 8643547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
